Home// - Sofia 2 SARS Antigen Fluorescent Immunoassay
Are you sure you want to exit?
Any unsave changes will be lost.
Sofia 2 SARS Antigen Fluorescent Immunoassay
Quidel Corporation
Category
Case Management
Country
United States of America (USA), North America
Description
The Sofia 2 SARS Antigen Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from SARS-CoV-2. The Sofia 2 SARS Antigen FIA, with the Sofia 2 analyzer, provides automated and objective results in 15 minutes, allowing for testing of patients suspected of COVID-19/2019-nCoV in near-patient testing environments.